Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DM8V0UL)

Drug Name

ASP-9521 Drug Info

Indication

Disease Entry	ICD 11	Status	REF
Prostate cancer	2C82.0	Phase 1/2	[1]

Cross-matching ID

Molecule-Related Drug Atlas

Molecule Type:

DTT

Drug Status:

Approved Drug(s)

Patented Agent(s)

Download the Complete Related Drug List

Drug(s) Targeting Dihydrodiol dehydrogenase type I (AKR1C3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Flufenamic Acid	DMC8VNH	Dysmenorrhea	GA34.3	Approved	[3]
N-(benzimidazole/indole) benzoic acid derivative 2	DMOPUFM	N. A.	N. A.	Patented	[4]
N-(phenylamino)-benzoate derivative 1	DMNIWVG	N. A.	N. A.	Patented	[4]
Indomethacin analog 3	DM53JXE	N. A.	N. A.	Patented	[4]
Indomethacin analog 2	DMKFPJ7	N. A.	N. A.	Patented	[4]
Beta-naphthylacetic acids derivative 1	DM5KTDY	N. A.	N. A.	Patented	[4]
Indomethacin analog 1	DM3E5V6	N. A.	N. A.	Patented	[4]
N-(naphthylamino)-benzoate derivative 1	DM310ES	N. A.	N. A.	Patented	[4]
N-(benzimidazolylcarbonyl)-piperidine derivative 1	DM541QW	N. A.	N. A.	Patented	[4]
Nitrogen/sulfur-substituted estrene derivative 1	DMD7OW0	N. A.	N. A.	Patented	[4]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Dihydrodiol dehydrogenase type I (AKR1C3)	TT5ZWB6	AK1C3_HUMAN	Modulator	[2]

------------------------------------------------------------------------------------

References

1	ClinicalTrials.gov (NCT01352208) Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients. U.S. National Institutes of Health.
2	Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. 2014 Oct;32(5):995-1004.
3	Ouellet M, Percival MD: Effect of inhibitor time-dependency on selectivity towards cyclooxygenase isoforms. Biochem J. 1995 Feb 15;306 ( Pt 1):247-51.
4	Aldo-Keto Reductase (AKR) 1C3 inhibitors: a patent review.Expert Opin Ther Pat. 2017 Dec;27(12):1329-1340.